Eton Pharmaceuticals, Inc. (ETON): Price and Financial Metrics
ETON Price/Volume Stats
| Current price | $4.73 | 52-week high | $5.81 |
| Prev. close | $4.65 | 52-week low | $1.95 |
| Day low | $4.55 | Volume | 113,900 |
| Day high | $4.89 | Avg. volume | 193,261 |
| 50-day MA | $3.86 | Dividend yield | N/A |
| 200-day MA | $3.64 | Market Cap | 121.34M |
ETON Stock Price Chart Interactive Chart >
ETON POWR Grades
- Sentiment is the dimension where ETON ranks best; there it ranks ahead of 89.74% of US stocks.
- ETON's strongest trending metric is Momentum; it's been moving down over the last 179 days.
- ETON's current lowest rank is in the Momentum metric (where it is better than 9.4% of US stocks).
ETON Stock Summary
- ETON's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 477.38 -- higher than 93.61% of US-listed equities with positive expected earnings growth.
- Over the past twelve months, ETON has reported earnings growth of -102.88%, putting it ahead of merely 13.67% of US stocks in our set.
- Revenue growth over the past 12 months for ETON PHARMACEUTICALS INC comes in at 70.58%, a number that bests 92.37% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to ETON PHARMACEUTICALS INC, a group of peers worth examining would be LZ, SSTI, AVPT, BMBL, and BLBX.
- Visit ETON's SEC page to see the company's official filings. To visit the company's web site, go to www.etonpharma.com.
ETON Valuation Summary
- ETON's price/sales ratio is 3.9; this is 105.26% higher than that of the median Healthcare stock.
- ETON's price/earnings ratio has moved down 483.4 over the prior 59 months.
Below are key valuation metrics over time for ETON.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| ETON | 2023-09-18 | 3.9 | 6.9 | -491.0 | 314.9 |
| ETON | 2023-09-15 | 4.3 | 7.6 | -542.7 | 353.2 |
| ETON | 2023-09-14 | 4.9 | 8.6 | -617.1 | 408.2 |
| ETON | 2023-09-13 | 4.5 | 8.0 | -570.1 | 373.4 |
| ETON | 2023-09-12 | 4.6 | 8.1 | -577.8 | 379.1 |
| ETON | 2023-09-11 | 4.5 | 8.0 | -568.8 | 372.5 |
ETON's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ETON has a Quality Grade of C, ranking ahead of 51.85% of graded US stocks.
- ETON's asset turnover comes in at 0.663 -- ranking 45th of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows ETON's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.663 | 0.885 | -1.378 |
| 2021-03-31 | 0.639 | 0.867 | -1.807 |
| 2020-12-31 | 0.002 | -6.333 | -4.051 |
| 2020-09-30 | 0.028 | -0.053 | -3.354 |
| 2020-06-30 | 0.037 | -0.009 | -4.187 |
| 2020-03-31 | 0.034 | 0.005 | -4.883 |
ETON Price Target
For more insight on analysts targets of ETON, see our ETON price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.00 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Eton Pharmaceuticals, Inc. (ETON) Company Bio
Eton Pharmaceuticals Inc. Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.
Latest ETON News From Around the Web
Below are the latest news stories about ETON PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ETON as an investment opportunity.
Here's Why 'Trend' Investors Would Love Betting on Eton Pharmaceuticals, Inc. (ETON)Eton Pharmaceuticals, Inc. (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. |
Eton Pharmaceuticals, Inc. (NASDAQ:ETON): Are Analysts Optimistic?We feel now is a pretty good time to analyse Eton Pharmaceuticals, Inc.'s ( NASDAQ:ETON ) business as it appears the... |
Eton Pharmaceuticals (ETON): A Modestly Undervalued Stock Worth Your AttentionDelving into the intrinsic value and financial health of Eton Pharmaceuticals Inc |
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceDEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows: Date:Wednesday, September 13, 2023 Time:9:00am ET To schedule a 1x1 meeting with the Company, please contact Corporate Access at |
Eton Pharmaceuticals, Inc. (ETON) Hits Fresh High: Is There Still Room to Run?Eton Pharmaceuticals, Inc. (ETON) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. |
ETON Price Returns
| 1-mo | 5.82% |
| 3-mo | 19.44% |
| 6-mo | 17.66% |
| 1-year | 117.97% |
| 3-year | -44.74% |
| 5-year | N/A |
| YTD | 67.73% |
| 2022 | -34.27% |
| 2021 | -47.23% |
| 2020 | 12.92% |
| 2019 | 17.65% |
| 2018 | N/A |
Continue Researching ETON
Want to do more research on Eton Pharmaceuticals Inc's stock and its price? Try the links below:Eton Pharmaceuticals Inc (ETON) Stock Price | Nasdaq
Eton Pharmaceuticals Inc (ETON) Stock Quote, History and News - Yahoo Finance
Eton Pharmaceuticals Inc (ETON) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...